Medication info
Lamifin Tablet (Terbinafine Hydrochloride)

Lamifin Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Kolon Pharmaceutical Co., Ltd.
Appearance
White to off-white round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201402707 · Approved 2014.06.17 · Insurance code 670303780

Summary

Main use
Treatment of onychomycosis, dermatomycosis (tinea pedis, tinea corporis, etc.), and tinea capitis
Who takes it
Adults · Children
Adult dose
125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. 3 months of treatment is usually sufficient for toenail infections, but in some patients, 6 months or longer may be required. The treatment period may be longer in patients with slow nail growth. For patients with a creatinine clearance of less than 50 mL/min, reduce the daily dose by 1/2.
Child dose
Administer to children 2 years of age and older. Administration is not recommended for children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks 1) Body weight less than 20 kg (under 5 years of age): Administer 62.5 mg once daily. As experience with treatment is limited, the decision to administer should be made after considering the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years of age): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years of age): Administer 250 mg once daily.

Ingredients

Manufacturer
Kolon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, dermatomycosis (tinea pedis, tinea corporis, etc.), and tinea capitis

  • Dermatophyte infections
  • tinea pedis
  • tinea corporis
  • tinea capitis
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used in adults for the treatment of tinea pedis, tinea corporis, tinea capitis, and onychomycosis caused by dermatophytes as well as tinea capitis in children.

How to take

Adult dose

125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. 3 months of treatment is usually sufficient for toenail infections, but in some patients, 6 months or longer may be required. The treatment period may be longer in patients with slow nail growth. For patients with a creatinine clearance of less than 50 mL/min, reduce the daily dose by 1/2.

Child dose

Administer to children 2 years of age and older. Administration is not recommended for children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks 1) Body weight less than 20 kg (under 5 years of age): Administer 62.5 mg once daily. As experience with treatment is limited, the decision to administer should be made after considering the benefits and risks of treatment. 2) Body weight 20~40 kg (5~12 years of age): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years of age): Administer 250 mg once daily.

Precautions

This drug is not recommended for patients with chronic liver disease or active liver disease. Before using this medication, the patient's liver disease status and history must be confirmed. Liver function abnormalities may occur regardless of liver disease history; therefore, regular liver function tests should be conducted before and during treatment. If liver function test values rise, the use of this medication must be discontinued immediately. If symptoms such as nausea, loss of appetite, fatigue, vomiting, pain in the right upper abdomen, jaundice, dark urine, or diarrhea occur during treatment, the patient must inform a doctor immediately. If these symptoms occur, this drug should be discontinued, and liver function tests should be performed. This medication can rarely cause severe liver failure, which may necessitate death or a liver transplant, so if signs of liver damage appear, treatment must be stopped immediately, and liver function should be monitored regularly. This drug should not be used in patients who have had allergic reactions to this drug or its components, those with chronic or active liver disease, blood disorders, severe renal failure, nursing mothers, or infants under 2 years old. Patients with lactose intolerance should also be cautious about using this medication. Careful administration should be observed for patients with impaired kidney function, elderly individuals, and children weighing less than 20 kg, and treatment should be stopped immediately if severe skin reactions occur. Patients with psoriasis or systemic lupus erythematosus should be cautious when using this medication. Patients should be regularly monitored for liver function, blood tests, skin condition, musculoskeletal symptoms, etc., and must consult with a doctor immediately if any abnormal symptoms occur. It is advisable to avoid driving or operating machinery if symptoms such as dizziness occur during the use of this medication. This medication may interact with other drugs, so if other medications are being taken, the patient must inform their doctor or pharmacist, and dosage adjustments may be necessary. Women of childbearing age should be cautious as there may be menstrual irregularities when used with oral contraceptives, and this medication's safety during pregnancy has not been established, so it should only be used when necessary. Nursing women should stop breastfeeding when taking this medication. In children, particularly those under 2 years of age, there is a lack of experience in administration, so careful consideration is advised, and elderly patients may require caution as the drug can remain in the body longer due to liver and kidney function decline. Overdose may result in headaches, nausea, abdominal pain, and dizziness, and immediate medical attention should be sought for proper treatment. This medication should be kept out of reach of children, not moved to other containers, stored away from direct sunlight, and kept at room temperature.

Side effects

Liver and gallbladder dysfunction, hepatitis, bile stasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated liver enzymes, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reactions, skin and mucous membrane syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesiculobullous dermatitis, psoriasiform rash, exacerbation of psoriasis, alopecia, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, sensation of chest tightness, urticaria, erythema, facial edema, lymphedema, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, upper abdominal discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste disorder, dizziness, drowsiness, sensory abnormalities, sensory reduction, decreased attention, insomnia, elevated BUN, frequent urination, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated serum total cholesterol, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorder, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased visual acuity, hearing loss, auditory impairment, vasculitis, permanent anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight, sealed container and kept at a temperature between 1 to 30 degrees Celsius. Storing it this way can maintain the drug's efficacy for a longer period.

Appearance and packaging

Appearance

White to off-white round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.